InflaRx (NASDAQ:IFRX) Short Interest Update

InflaRx (NASDAQ:IFRX) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 415,200 shares, a drop of 13.7% from the January 15th total of 481,300 shares. Based on an average daily trading volume, of 305,500 shares, the days-to-cover ratio is presently 1.4 days.

Institutional Investors Weigh In On InflaRx

Hedge funds have recently bought and sold shares of the business. Raymond James Financial Inc. bought a new position in InflaRx during the 4th quarter worth approximately $1,576,000. Northern Trust Corp lifted its holdings in InflaRx by 1,933.1% during the 4th quarter. Northern Trust Corp now owns 666,845 shares of the company’s stock worth $1,647,000 after buying an additional 634,045 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in InflaRx during the 4th quarter worth approximately $55,000. Walleye Capital LLC bought a new stake in shares of InflaRx in the 4th quarter worth approximately $51,000. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of InflaRx by 20.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after purchasing an additional 19,000 shares during the last quarter. Institutional investors and hedge funds own 42.39% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of InflaRx in a research note on Thursday, January 16th.

InflaRx Stock Performance

IFRX stock opened at $2.00 on Tuesday. InflaRx has a 1 year low of $1.16 and a 1 year high of $2.82. The stock has a 50-day simple moving average of $2.41 and a 200-day simple moving average of $1.92. The firm has a market cap of $117.76 million, a P/E ratio of -1.85 and a beta of 1.63.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.